Zejula, known chemically as niraparib, is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of ovarian cancer. Like many medications, it can cause side effects.
Common Side Effects of Zejula
The most frequently reported side effects of Zejula include myelosuppression, which refers to the suppression of bone marrow activity. This can lead to a decrease in blood cell counts. Specific blood count changes commonly observed are:
* Thrombocytopenia: Low platelet count, which can increase the risk of bleeding.
* Anemia: Low red blood cell count, potentially causing fatigue and weakness.
* Neutropenia: Low white blood cell count, which can make patients more susceptible to infections.
Other common side effects reported by patients taking Zejula include:
* Nausea and vomiting
* Fatigue
* Constipation
* Abdominal pain
* Headache
* Hypertension (high blood pressure)
* Decreased appetite
* Dyspepsia (indigestion)
* Dizziness
These side effects are often manageable and can typically be addressed by a healthcare provider through dose adjustments or supportive care [1].
Serious and Less Common Side Effects
While less frequent, some serious side effects can occur with Zejula use. These may require immediate medical attention.
* Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): These are serious bone marrow disorders that have been reported in patients treated with PARP inhibitors, including niraparib. The risk appears to be higher in patients with pre-existing bone marrow abnormalities or those who have received prior chemotherapy [1].
* Interstitial Lung Disease (ILD)/Pneumonitis: Inflammation of the lungs, presenting with symptoms such as shortness of breath, cough, and fever, is a rare but serious side effect.
* Embryo-Fetal Toxicity: Zejula can cause harm to an unborn fetus. Women of reproductive potential should use effective contraception during treatment and for a specified period after the last dose [1].
Managing Zejula Side Effects
Healthcare providers closely monitor patients for the development of side effects. Regular blood tests are crucial to detect changes in blood cell counts. If side effects occur, they are typically managed by:
* Dose Interruption or Reduction: The dosage of Zejula may be temporarily stopped or permanently reduced.
* Supportive Care: Medications may be prescribed to manage symptoms like nausea, vomiting, or constipation. Growth factors might be used to help increase blood cell counts.
Patients are advised to report any new or worsening symptoms to their doctor promptly [1].
How Long Do Side Effects Last?
The duration of side effects can vary significantly from person to person and often depends on the specific side effect and how the individual's body responds to the medication and its management. Some side effects, like nausea, may improve over time as the body adjusts to the drug. Others, such as changes in blood counts, are managed through monitoring and medical intervention, with levels typically returning to normal with dose adjustments or treatment discontinuation. The risk of long-term effects like MDS/AML is a consideration throughout treatment and potentially beyond [1].
Zejula and Its Patent Status
Information on Zejula's patent status, including expiry dates and any related litigation or challenges, can be found through specialized drug patent databases. These resources track patent protection for pharmaceutical products and can provide insights into when generic competition might be possible. DrugPatentWatch.com is a source for such information. For specific details on Zejula's patents, one would consult such a platform [2].